Sentences with phrase «over time in program»

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

The New York Times reported yesterday that, in October of last year, Uber altered its testing program by putting only one safety monitor in each autonomous car rather than two, over the safety concerns of some employees.

Participating in this sort of program may mean you pay more interest over time, but it can help you reduce minimum monthly payments and put that extra capital toward a startup.

Candidates can complete the program in a few different ways: full - time on campus in Sydney, Nova Scotia over one year; part - time classes on alternate weekends over two years in Toronto, Kingston, Saskatoon, Edmonton, or Whitehorse; or a one - month residency on campus in Sydney each July for three years.

There may be a «lull» in the tensions over North Korea's nuclear program, but leader Kim Jong Un is merely playing for time, says Eurasia Group's Meredith Sumpter.

«Over time, we would expect the new loyalty program to help drive traffic / basket / sales at Canadian Tire,» she wrote in a research note.

Clinton's apparent popularity likely stems from her developing connections in the tech sector over a longer period of time than other Oval Office contenders, according to Mark Schmitt, director of the political reform program at independent think tank New America Foundation.

Indeed, there was something magical about the time, where a mix of national pride and a shame over Soviet advances led us to cheer on a government program that led us to dominate the USSR in the dome of heaven itself.

The recipient of several Bronze Stars and Service Medals (among other awards), Dunbar had to leave his UCLA EMBA program for a time so he could lead special forces operations inside Afghanistan, which included (in Dunbar's words) «11 different battalions, from 7 different countries, 13 different governmental and non-governmental agencies with over 6,000 personnel with no positional authority over the networked organization.»

Over the past 17 years, Thunderbird has experienced a 75 % decrease in enrollment for its full - time MBA program.

Employees vest in the program over time, just as in a 401 (k), and can only cash out when they retire, are laid off, resign, or are fired.

Remember that when your in - location mobile - marketing strategy is a seamless component of the overall marketing program, your customers will learn over time that they're going to receive in - location mobile communications and messages only by walking into a specific, physical location.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tPrograms (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (tprograms; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.

Some other added benefits from taking out a loan with OneMain are that you'll have the option of paying off your loan over a longer period of time, and that you might qualify participate in a rewards program and earn points to redeem for gift cards at national stores and restaurants.

In a video programming business that will be increasingly dominated by over-the-top distribution and skinnier bundles, «reach» — the actual percentage of viewers that watch a channel over a set time period — will have a much greater role in defining consumer pricinIn a video programming business that will be increasingly dominated by over-the-top distribution and skinnier bundles, «reach» — the actual percentage of viewers that watch a channel over a set time period — will have a much greater role in defining consumer pricinin defining consumer pricing.

The budget also included a one - time $ 1 billion investment in the renamed Canada Workers Benefit, $ 2 billion over five years in a new Indigenous Skills and Employment Training Program, $ 448 million over five years in the Canada Summer Jobs pProgram, $ 448 million over five years in the Canada Summer Jobs programprogram.

«On October 24, 2017, our board of directors authorized a $ 150.0 million stock repurchase program, allowing us to repurchase shares of our common stock over a two - year period from time to time at various prices in the open market or through private transactions.

As I talked about in the 14 minute video above, while you can invest in this program for one payment of $ 10,000 or 4 payments over the 4 month program of $ 2,500 each month you're gaining access to more than $ 50,000 worth of value and content in this time that will help you become a world class value investor in a fraction of the time it would normally take.

And that means over this time period, we will have generated more than $ 2 billion in total savings from [the current cost plan] and the restructuring program.

Itâ $ ™ s over and time to move onto announcements, offering or whatever comes next in this churchâ $ ™ s program.

Not throwing the Magisterium of the Church over programs here, in the U.S., on which Rome has neither specifically spoken and which it doesn't understand (which we don't even fully understand at this time).

These broadcasters, who once could not get enough time, have been so effective in their struggle that they now hold a virtual monopoly over air - time used for religious programming, having forced most other religious programs off the air by their cut - throat purchase of time.

«Ultimately the weakest will be hit three times over,» Ryan writes, «by rising costs, by drastic cuts to programs they rely on, and by the collapse of individual support for charities that help the hungry, the homeless, the sick, refugees and others in need.»

Each of these schemes has its advantages; on the whole the last is probably best, since it provides for a certain variety in the over-all program and makes it possible for those who attend not only to take part in one large meeting where the whole group is stimulated by consideration of a single topic over a considerable period of time, but also to share in special «interest groups» which will give them the opportunity to follow up lines of thought that particularly interest them or to explore problems that are peculiarly relevant to their own needs and concerns.

The school must not be undertaken, that is, as a brief experiment only; it must be a genuine part of a long - range parish program over several years, with the definite intention of continuing the school so that it will be accepted in time as a normal and expected part of the total life of the congregation.

For several decades, until his death this past July, the English painter stuck stubbornly to his program of stark, severe portraiture, ignoring the many trend - waves that washed over the art world in that time.

To understand fully the implications of the characteristic audience of paid - time religious programs, one must consider the historical context of the changes that have taken place in religious broadcasting over the past 15 years.

The author examines the debate in the church over the growth of paid - time religious programs which has centered on several major issues, including the nature of the church, its mission, evangelism, pastoral care and counseling, and the social and political impact, and also the communication aspects: one way versus interactive communication.

It is this reality that contradicts the claim by the paid - time broadcasters that by cultivating audience support they have been able to free themselves from network and local station control over their programs and thus act independently in proclaiming the gospel.

The debate in the church over the growth of paid - time religious programs has centered on several major issues.

For best results supplements should be taken as directed over time, at maximum dosage in conjunction with a healthy diet and regular exercise program.

When good sanitation practices in the food manufacturing environment are consistently, even habitually, applied over time, all of the company's food safety programs are enhanced.

Open to all California wineries and vineyards as a voluntary option, CSWA's new program requires applicants to meet 58 prerequisite criteria that are among the 227 best management practices in the Code of Sustainable Winegrowing Practices Self - Assessment Workbook to be eligible for the program, assess winery and / or vineyard operations, create and implement an annual action plan and show improvement over time.

She changed over to WordPress and off of blogger so maybe your anti virus program will allow you in this time (prob why the pic disappeared too).

In this context, the paper examines the National Rice Program and sector performance over time, and analyzes government spending in connection with the prograIn this context, the paper examines the National Rice Program and sector performance over time, and analyzes government spending in connection with the pProgram and sector performance over time, and analyzes government spending in connection with the prograin connection with the programprogram.

«While it didn't herald the next step in the program many hoped it would, this game was still the only win Georgia claimed over Steve Spurrier during his time in Gainesville.

Featured in the New York Times, this highly respected program has grown to coach over 5,000 children and youth per year between New York, Los Angeles, and San Francisco.

St. Louis, which at the time was regarded as having one of the top programs in the nation, entered the matchup with an 11 -2-1 record against California teams, including a win in 1991 over Bakersfield that snapped Bakersfield's 39 - game win streak.

For all its victories, Miami football has been worse in more ways over a longer period of time than any other intercollegiate athletic program in memory.

Your dedicated efforts and valuable time produce terrific sports programs for over 5,000 children in the Lafayette Moraga area.

Live, televised sporting events represent the last bastion of programming where a captive audience actually watches in real time, eyes glued to the screen, rather than via DVR where ads can be skipped over with the simple push of a button.

Today, top high school rugby players have often learned to compete over 6 or 8 seasons, and in some cases, played under the same coach, or program, the entire time.

Notre Dame has been consistently one of the top programs in college soccer over the past several seasons, especially the year the program was crowned national champions for the first time at then - PPL Park back in 2013.

In 2018, Marquette women's lacrosse will be looking to qualify for the Big East tournament for the first time in program history as well as attempting to finish over.500 for the first time as welIn 2018, Marquette women's lacrosse will be looking to qualify for the Big East tournament for the first time in program history as well as attempting to finish over.500 for the first time as welin program history as well as attempting to finish over.500 for the first time as well.

Over the past 5 years, I have attended Sharyn's early childhood programs, parenting sessions and am currently in a parlor group lead by Sharyn for the second time around.

Such programs - with at least 16 under way in Illinois and others planned - provide children with creative and fun ways to spend their time, while giving schools a means to deal with students who show up early each day or stay long after classes are over.

Delivered four times a year to over 32,000 households in Arlington Heights, this Program Guide is an essential recreation - planning tool for residents.

And at a time when over 17 million American children are growing up in food - insecure households, the House GOP proposes a cut of «about $ 650 million — or 10 percent — from the Women, Infants and Children program that feeds and educates mothers and their children.»

One example of how to do this is the Nurse Family Partnership, a program that has provided intensive support to first - time at - risk mothers in the United States for over three decades.